Chimerix, Inc.

Equities

CMRX

US16934W1062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.8844 ^USD	-5.14%		-7.94%	-8.11%

Mar. 21	Chimerix Appoints Marc D. Kozin to Board of Directors	CI
Feb. 29	Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024

Chimerix to Present at Wedbush PacGrow Healthcare Conference

August 02, 2022 at 07:01 am EDT

DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Source: Chimerix, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Latest news about Chimerix, Inc.

Chimerix Appoints Marc D. Kozin to Board of Directors	Mar. 21	CI
Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000	Feb. 29	MT
Chimerix Announces Board Changes	Dec. 29	CI
Chimerix Names Michelle LaSpaluto Finance Chief	Dec. 04	MT
Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer	Dec. 04	CI
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer	Nov. 16	CI
Transcript : Chimerix, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000	Nov. 02	MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery	23-08-16	CI
Transcript : Chimerix, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000	23-08-03	MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Chimerix Names Michael Andriole as Chief Executive Officer	23-06-27	MT
Chimerix, Inc. Announces CEO Changes, Effective on August 1, 2023	23-06-27	CI
Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023	23-06-27	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Comp Value Index	23-06-23	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 3000 Index	23-06-23	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Value Index	23-06-23	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Index	23-06-23	CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Index	23-06-23	CI

Chart Chimerix, Inc.

Duration

Period

More charts

Company Profile

Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chimerix, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8844 USD

Average target price

7.333 USD

Spread / Average Target

+729.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHIMERIX, INC.	-8.11%	83.17M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs